This proposal seeks a renewal of funding for the United States based International Breast Cancer Study Group (IBCSG) Statistical and Data Management Center, a resource that contributes to International-US collaboration in the following areas: 1. Access to the IBCSG clinical database of 13,000 breast cancer patients enrolled in large-scale, randomized clinical trials with up to 21 years' maximum follow-up. 2. Access to the IBCSG tissue bank database for more than 1,000 patients with 10 years' median follow-up. 3. Expertise of statistical and medical investigators. 4. Collaboration in the development of the IBCSG research agenda. This resource gives NCI an opportunity to significantly improve their understanding of prognosis and treatment of women with operable breast cancer. The number of randomized trials that can be conducted in the United States cannot answer all of the questions about this population of patients. Support of this proposal for an IBCSG-NCI partnership will result in important new information about the appropriate clinical use of combined chemoendocrine therapy, timing and duration of adjuvant chemotherapy, endocrine therapies, management strategies for the axilla, and high dose chemotherapy. The long-range goal of the IBCSG is to find the best possible treatments for operable breast cancer.
The specific aims of this application comprise the major areas of research toward this goal. 1. To provide US-based statistical and data management collaboration for the design, conduct, analysis, and reporting of IBCSG randomized clinical trials evaluating adjuvant therapies. 2. To facilitate correlative research by providing access to their uniformly treated and followed populations of patients with tissue collection at diagnosis. 3. To facilitate collaboration on database studies to identify and confirm the relationship between characteristics of breast cancer patients and/or tumors and response to adjuvant therapies. 4. To enhance collaboration between the IBCSG and US cooperative groups in the area of quality-of-life evaluation for patients with breast cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Francis, Prudence A; Pagani, Olivia; Fleming, Gini F et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379:122-137
Wapnir, Irene L; Price, Karen N; Anderson, Stewart J et al. (2018) Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol 36:1073-1079
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122
Regan, M M; Walley, B A; Francis, P A et al. (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225-2232
Ribi, Karin; Bernhard, Jürg; Luo, Weixiu et al. (2016) Reply to F. Tomao et al. J Clin Oncol 34:4189-4190
Regan, Meredith M; Francis, Prudence A; Pagani, Olivia et al. (2016) Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221-31
Bellet, Meritxell; Gray, Kathryn P; Francis, Prudence A et al. (2016) Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. J Clin Oncol 34:1584-93
Colleoni, Marco; Gray, Kathryn P; Gelber, Shari et al. (2016) Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol 34:3400-8
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Karlsson, Per; Cole, Bernard F; Price, Karen N et al. (2016) Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII. Int J Radiat Oncol Biol Phys 96:273-279

Showing the most recent 10 out of 71 publications